Mepolizumab for treating severe eosinophilic asthma [ID3750]
In development [GID-TA10622] Expected publication date: 03 February 2021
Search results
562 results
-
-
Tafamidis for treating transthyretin amyloid cardiomyopathy [ID1531]
In development [GID-TA10451] Expected publication date: TBC
-
Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma [ID1313]
In development [GID-TA10312] Expected publication date: 24 February 2021
-
Relugolix with oestradiol and norethindrone acetate for heavy menstrual bleeding associated with uterine fibroids [ID3842]
In development [GID-TA10734] Expected publication date: TBC
-
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma [ID1444]
In development [GID-TA10477] Expected publication date: 22 September 2021
-
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) [ID1585]
In development [GID-TA10538] Expected publication date: TBC
-
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma in people who have received at least 3 prior therapies [ID1442]
In development [GID-TA10672] Expected publication date: TBC
-
Non-bisphosphonates for treating osteoporosis [ID901]
In development [GID-TA10072] Expected publication date: 19 May 2021
-
Multiple myeloma - lenalidomide (maintenance, post autologous stem cell transplantation) [ID475]
In development [GID-TAG430] Expected publication date: 24 February 2021
-
Pembrolizumab with platinum-based chemotherapy for untreated advanced oesophageal cancer [ID3741]
In development [GID-TA10613] Expected publication date: 13 October 2021
-
Trifluridine–tipiracil for treating metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID1507]
In development [GID-TA10456] Expected publication date: 27 January 2021
-
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor [ID1468]
In development [GID-TA10351] Expected publication date: 27 January 2021
-
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (CDF review of TA593) [ID3755]
In development [GID-TA10675] Expected publication date: 17 June 2021
-
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (CDF Review of TA558) [ID1681]
In development [GID-TA10644] Expected publication date: 17 March 2021
-
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [ID2727]
In development [GID-TA10674] Expected publication date: 17 March 2021
-
Anakinra for treating active Stills disease [ID1463]
In development [GID-TA10392] Expected publication date: TBC
-
Nivolumab for adjuvant treatment of oesophageal or gastro-oesophageal junction cancer [ID1676]
In development [GID-TA10743] Expected publication date: 17 November 2021
-
Ponesimod for treating relapsing multiple sclerosis [ID1393]
In development [GID-TA10556] Expected publication date: 17 November 2021
-
Nintedanib for treating progressive fibrosing interstitial lung disease [ID1599]
In development [GID-TA10520] Expected publication date: 15 September 2021
-
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 therapies [ID3805]
In development [GID-TA10671] Expected publication date: TBC
-
Esketamine for treatment-resistant depression (ID1414)
In development [GID-TA10371] Expected publication date: TBC
-
Brolucizumab for treating wet age-related macular degeneration [ID1254]
In development [GID-TA10455] Expected publication date: 03 February 2021
-
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 1 prior therapy [ID1557]
In development [GID-TA10485] Expected publication date: 23 June 2021
-
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency [ID3802]
In development [GID-TA10670] Expected publication date: TBC
-
AR101 for treating peanut allergy [ID1282]
In development [GID-TA10713] Expected publication date: TBC
-
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID1680]
In development [GID-TA10551] Expected publication date: 10 February 2021
-
Pegcetacoplan for previously treated paroxysmal nocturnal haemoglobinuria [ID3746]
In development [GID-TA10651] Expected publication date: 02 February 2022
-
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]
In development [GID-TA10481] Expected publication date: 18 August 2021
-
Filgotinib for treating moderate to severe rheumatoid arthritis ID1632
In development [GID-TA10541] Expected publication date: 24 February 2021
-
Fenfluramine for treating Dravet syndrome [ID1109]
In development [GID-TA10373] Expected publication date: 21 April 2021
-
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma [ID1609]
In development [GID-TA10498] Expected publication date: 13 October 2021
-
Cenobamate for focal onset seizures in epilepsy [ID1553]
In development [GID-TA10661] Expected publication date: 13 October 2021
-
Sotorasib for previously treated KRAS G12C mutated, locally advanced or metastatic non-small-cell lung cancer [ID3780]
In development [GID-TA10639] Expected publication date: TBC
-
Mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders ID1488
In development [GID-TA10432] Expected publication date: TBC
-
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1647]
In development [GID-TA10703] Expected publication date: 21 July 2021
-
Selective internal radiation therapies for treating hepatocellular carcinoma [ID1276]
In development [GID-TA10381] Expected publication date: TBC
-
Fedratinib for disease-related splenomegaly and symptoms in myelofibrosis [ID1501]
In development [GID-TA10406] Expected publication date: TBC
-
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm [ID1556]
In development [GID-TA10482] Expected publication date: 21 July 2021
-
Nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer (CDF review TA484) [ID1572]
In development [GID-TA10513] Expected publication date: TBC
-
Berotralstat for preventing acute attacks of hereditary angioedema [ID1624]
In development [GID-TA10650] Expected publication date: 25 August 2021
-
Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]
In development [GID-TA10612] Expected publication date: 21 July 2021
-
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 alterations [ID3740]
In development [GID-TA10619] Expected publication date: TBC
-
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy [ID3735]
In development [GID-TA10624] Expected publication date: 23 June 2021
-
Spasticity (after stroke) - botulinum toxin type A [ID768]
In development [GID-TAG499] Expected publication date: TBC
-
Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]
In development [GID-TA10105] Expected publication date: TBC
-
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]
In development [GID-TA10089] Expected publication date: 15 November 2017
-
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]
In development [GID-TA10458] Expected publication date: 19 May 2021
-
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340
In development [GID-TA10313] Expected publication date: TBC
-
Nivolumab for treating resected high-risk invasive urothelial cancer [ID2694]
In development [GID-TA10742] Expected publication date: TBC
-
Solriamfetol for treating excessive waketime sleepiness caused by narcolepsy [ID1602]
In development [GID-TA10524] Expected publication date: TBC